@article{83b985136aec402c83139db08b143b24,
title = "The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma",
abstract = "Treatment of patients with COVID-19 using convalescent plasma from recently recovered patients has been shown to be safe, but the time course of change in clinical status following plasma transfusion in relation to baseline disease severity has not yet been described. We analyzed short, descriptive daily reports of patient status in 7,180 hospitalized recipients of COVID-19 convalescent plasma in the Mayo Clinic Expanded Access Program. We assessed, from the day following transfusion, whether the patient was categorized by his or her physician as better, worse or unchanged compared to the day before, and whether, on the reporting day, the patient received mechanical ventilation, was in the ICU, had died or had been discharged. Most patients improved following transfusion, but clinical improvement was most notable in mild to moderately ill patients. Patients classified as severely ill upon enrollment improved, but not as rapidly, while patients classified as critically ill/end-stage and patients on ventilators showed worsening of disease status even after treatment with convalescent plasma. Patients age 80 and over showed little or no clinical improvement following transfusion. Clinical status at the time of convalescent plasma treatment and age appear to be the primary factors in determining the therapeutic effectiveness of COVID-19 convalescent plasma among hospitalized patients.",
keywords = "COVID-19, SARS-CoV-2, antibodies, antibody therapy, convalescent plasma therapy",
author = "Tengfei Ma and Wiggins, {Chad C.} and Kornatowski, {Breanna M.} and Hailat, {Ra'ed S.} and Clayburn, {Andrew J.} and Guo, {Winston L.} and Johnson, {Patrick W.} and Senefeld, {Jonathon W.} and Klassen, {Stephen A.} and Baker, {Sarah E.} and Bruno, {Katelyn A.} and Fairweather, {De Lisa} and Wright, {R. Scott} and Carter, {Rickey E.} and Chenxi Li and Joyner, {Michael J.} and Paneth, {Nigel S.}",
note = "Funding Information: This project has been funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096. Additionally, this study was supported in part by National Center for Advancing Translational Sciences (NCATS) grant UL1TR002377, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5T32DK07352 (to CW), National Heart, Lung, and Blood Institute (NHLBI) grant 5R35HL139854 (to MJ) and grant 1F32HL154320 (to JS), Natural Sciences and Engineering Research Council of Canada (NSERC) PDF-532926-2019 (to SK), National Institute of Allergy and Infectious Disease (NIAID) grants R21 AI145356, R21AI152318 and R21 AI154927 (to DF), Schwab Charitable Fund (Eric E Schmidt, Wendy Schmidt donors), United Health Group, National Basketball Association (NBA), Millennium Pharmaceuticals, Octapharma USA, Inc., and the Mayo Clinic. Funding Information: Conflict of Interest: This study received funding from Millennium Pharmaceuticals, Octapharma USA, Inc. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher Copyright: Copyright {\textcopyright} 2022 Ma, Wiggins, Kornatowski, Hailat, Clayburn, Guo, Johnson, Senefeld, Klassen, Baker, Bruno, Fairweather, Wright, Carter, Li, Joyner and Paneth.",
year = "2022",
month = jan,
day = "26",
doi = "10.3389/fmed.2021.707895",
language = "English (US)",
volume = "8",
journal = "Frontiers in Medicine",
issn = "2296-858X",
publisher = "Frontiers Media S. A.",
}